Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 15
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Consejos ergonómicos para los panaderos, Ergonomic advice for bakers

  • Piedrabuena Cuesta, Alicia
  • Oltra Pastor, Alfonso
  • Martínez Devincenzi, Gabriela Alejandra
  • Matey González, Francisco José
  • Marín Mico, Óscar Cristóbal
  • Ruiz Folgado, Raquel
  • Dominguez Morales, Montserrat
  • García Serrano, Fernando
  • García Hervás, Ana María
  • García Quismondo, Lucía
  • Riera Díaz, Manuel
[EN] During 2011, CEOPAN, FEAGRA-CCOO, FITAG-UGT and IBV developed a manual for technical assessment to prevent ergonomic risks in the bakery sector, thanks to the funds of the FPRL (IS-0099/2010). This project allowed the development of a simple, rapid and participatory tool for ergonomic risk assessment. This tool answered one of the great difficulties in the sector for the implementation of preventive measures: having simple tools available for entrepreneurs and employees in the context of microSMEs (more than 90% of companies of the bakery sector). In 2012 the same entities have developed a project to overcome another challenge of the sector: the difficulty to access to training caused by work schedules and because so small companies don¿t hire any prevention consultant for technical assessment. Specifically, partners have developed a set of audiovisual podcasts based on real environment, available through a web portal or mobile apps, in order to explain risk factors for employees and good practices to reduce them., [ES] En el marco de la asignación para los panaderos de recursos de la Fundación para la Prevención de Riesgos Laborales (Convocatoria de asignación de recursos del ejercicio 2011, IS-0110/2011, IS-0113/2011 e IS-0136/2011), CEOPAN, las federaciones sindicales FEAGRACCOO y FITAG-UGT y el Instituto de Biomecánica (IBV) han desarrollado un proyecto dirigido a presentar recomendaciones y buenas prácticas ergonómicas mediante mensajes audiovisuales disponibles a través de la web o de los dispositivos móviles de los trabajadores y empresarios del sector de panadería., Proyecto financiado por la Fundación para la Prevención de Riesgos Laborales en el marco de la Convocatoria de asignación de recursos del ejercicio 2011 (IS-0110/2011, IS-0113/2011 e IS-0136/2011).
Addi. Archivo Digital para la Docencia y la Investigación
Publication Artículo científico (JournalArticle)

Adiponectin, leptin, and IGF-1 are useful diagnostic and stratification biomarkers of NAFLD

  • Marques, Vanda
  • Afonso, Marta Bento
  • Bierig, Nina
  • Duarte-Ramos, Filipa
  • Santos Laso, Álvaro
  • Jiménez Agüero, Raúl
  • Eizaguirre Letamendia, Emma
  • Bujanda Fernández de Pierola, Luis
  • Pareja Megía, María J.
  • Luís, Rita
  • Costa, Adília
  • Machado, Mariana Verdelho
  • Alonso, Cristina
  • Arretxe Oliden, Enara
  • Alustiza Echeberria, José María
  • Krawczyk, Marcin
  • Lammert, Frank
  • Tiniakos, Dina G.
  • Flehmig, Bertram
  • Cortez-Pinto, Helena
  • Bañales Asurmendi, Jesús María
  • Castro, Rui E.
  • Normann, Andrea
  • Rodrigues, Cecilia M. P.
[EN] Background: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease where liver biopsy remains the gold standard for diagnosis. Here we aimed to evaluate the role of circulating adiponectin, leptin, and insulin-like growth factor 1 (IGF-1) levels as non-invasive NAFLD biomarkers and assess their correlation with the metabolome. Materials and Methods: Leptin, adiponectin, and IGF-1 serum levels were measured by ELISA in two independent cohorts of biopsy-proven obese NAFLD patients and healthy-liver controls (discovery: 38 NAFLD, 13 controls; validation: 194 NAFLD, 31 controls) and correlated with clinical data, histology, genetic parameters, and serum metabolomics. Results: In both cohorts, leptin increased in NAFLD vs. controls (discovery: AUROC 0.88; validation: AUROC 0.83; p < 0.0001). The leptin levels were similar between obese and non-obese healthy controls, suggesting that obesity is not a confounding factor. In the discovery cohort, adiponectin was lower in non-alcoholic steatohepatitis (NASH) vs. non-alcoholic fatty liver (AUROC 0.87; p < 0.0001). For the validation cohort, significance was attained for homozygous for PNPLA3 allele c.444C (AUROC 0.63; p < 0.05). Combining adiponectin with specific serum lipids improved the assay performance (AUROC 0.80; p < 0.0001). For the validation cohort, IGF-1 was lower with advanced fibrosis (AUROC 0.67, p<0.05), but combination with international normalized ratio (INR) and ferritin increased the assay performance (AUROC 0.81; p < 0.01). Conclusion: Serum leptin discriminates NAFLD, and adiponectin combined with specific lipids stratifies NASH. IGF-1, INR, and ferritin distinguish advanced fibrosis., CR was funded by FEDER through the COMPETE program and by national funds through Fundação para a Ciência e a Tecnologia (PTDC/MED-FAR/29097/2017—LISBOA-01- 0145-FEDER-029097) and by European Horizon 2020 (H2020- MSCA-RISE-2016-734719). This work was also supported by Fundação para a Ciência e Tecnologia (PD/BD/135467/2017) and Portuguese Association for the Study of Liver/MSD 2017. JB was funded by Spanish Carlos III Health Institute (ISCIII) (PI15/01132, PI18/01075 and Miguel Servet Program CON14/00129 and CPII19/00008), co-financed by Fondo Europeo de Desarrollo Regional (FEDER), Instituto de Salud Carlos III (CIBERehd, Spain), La Caixa Scientific Foundation (HR17-00601), Fundación Científica de la Asociación Española Contra el Cáncer, and European Horizon 2020 (ESCALON project: H2020-SC1-BHC-2018-2020).
Addi. Archivo Digital para la Docencia y la Investigación
Publication Artículo científico (JournalArticle)

Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease

  • Caballero Camino, Francisco Javier
  • Rivilla de la Cruz, Iván
  • Herráez Aguilar, Elisa
  • Briz Sánchez, Oscar
  • Santos Laso, Álvaro
  • Izquierdo Sánchez, Laura
  • Lee-Law, Pui Y.
  • Rodrigues, Pedro M.
  • Muñoz Garrido, Patricia
  • Jin, Sujeong
  • Peixoto, Estanislao
  • Richard, Seth
  • Gradilone, Sergio A.
  • Perugorria Montiel, María Jesús
  • Esteller, Manel
  • Bujanda Fernández de Pierola, Luis
  • Marín, José J. G.
  • Bañales Asurmendi, Jesús María
  • Cossío Mora, Fernando Pedro
Background and Aims Polycystic liver diseases (PLDs) are genetic disorders characterized by progressive development of symptomatic biliary cysts. Current surgical and pharmacological approaches are ineffective, and liver transplantation represents the only curative option. Ursodeoxycholic acid (UDCA) and histone deacetylase 6 inhibitors (HDAC6is) have arisen as promising therapeutic strategies, but with partial benefits. Approach and Results Here, we tested an approach based on the design, synthesis, and validation of a family of UDCA synthetic conjugates with selective HDAC6i capacity (UDCA-HDAC6i). Four UDCA-HDAC6i conjugates presented selective HDAC6i activity, UDCA-HDAC6i #1 being the most promising candidate. UDCA orientation within the UDCA-HDAC6i structure was determinant for HDAC6i activity and selectivity. Treatment of polycystic rats with UDCA-HDAC6i #1 reduced their hepatomegaly and cystogenesis, increased UDCA concentration, and inhibited HDAC6 activity in liver. In cystic cholangiocytes UDCA-HDAC6i #1 restored primary cilium length and exhibited potent antiproliferative activity. UDCA-HDAC6i #1 was actively transported into cells through BA and organic cation transporters. Conclusions These UDCA-HDAC6i conjugates open a therapeutic avenue for PLDs., Supported by the Spanish Carlos III Health Institute (ISCIII; J.M. Banales: FIS PI15/01132, PI18/01075 and Miguel Servet Program CON14/00129; M.J. Perugorria: PI14/00399, PI17/00022; J.J.G. Marin: FIS PI16/00598) cofinanced by "Fondo Europeo de Desarrollo Regional" (FEDER); CIBERehd (ISCIII): J.M. Banales, M.J. Perugorria, L. Bujanda, and J.J.G. Marin; Spanish Ministry of Economy and Competitiveness (M. J. Perugorria: Ramon y Cajal Program RYC-2015-17755); IKERBASQUE, Basque foundation for Science (M.J. Perugorria and J.M. Banales), Spain; "Junta de Castilla y Leon" (J.J.G. Marin: SA06P17); " Diputacion Foral Gipuzkoa" (J.M. Banales: DFG15/010, DFG16/004; M.J. Perugorria: DFG18/114, DFG19/081), BIOEF (Basque Foundation for Innovation and Health Research: EiTB Maratoia BIO15/CA/016/BD to J.M. Banales), Department of Health of the Basque Country (J.M. Banales: 2017111010; M.J. Perugorria: 2019111024), and Euskadi RIS3 (J.M. Banales: 2016222001, 2017222014, and 2018222029; 2019222054); La Caixa Scientific Foundation (J.M. Banales: HR17-00601); "Fundacion Cientifica de la Asociacion Espanola Contra el Cancer" (AECC Scientific Foundation, to J.M. Banales and J.J.G. Marin); and "Centro Internacional sobre el Envejecimiento", Spain (J.J.G. Marin: OLD-HEPAMARKER, 0348-CIE-6-E). F.J. Caballero-Camino was funded by the Spanish Ministry of Science and Innovation (BES-2014-069148), A. Santos-Laso by the Basque Government (PRE_2018_2_0195), and Pui Y. Lee-Law by the European Association for the Study of the Liver (EASL; Sheila Sherlock Award). The Spanish Ministry of Science and Innovation supported F. P. Cossio: (CTQ2016-80375-P and CTQ2014-51912-REDC) as well as the Basque Government (F.P. Cossio: IT-324-07). I. Rivilla had a postdoctoral contract from the Donostia International Physics Center.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

CD3 aptamers promote expansion and persistence of tumor-reactive T cells for adoptive T cell therapy in cancer

  • Menon, Ashwathi Puravankara
  • Villanueva, Helena
  • Meraviglia-Crivelli, Daniel
  • Van Santen, Hisse M.
  • Hellmeier, Joschka
  • Zheleva, Angelina
  • Nonateli, Francesca
  • Peters, Timo
  • Wachsmann, Tassilo L.A.
  • Hernandez-Rueda, Mercedes
  • Huppa, Johannes B.
  • Schütz, Gerhard J.
  • Sevcsik, Eva
  • Moreno, Beatriz
  • Pastor, Fernando
Instituto Salud Carlos III financed with Feder Funds PI20-01132 (“A way to make Europe”) for F.P. This project has received funding from the European Union Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Action grant agreement no. 721358 and under the H2020-FETOPEN “DESTINATION” grant agreement no. 899833., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Gender differences in the incidence of and risk factors for hip fracture: A 16-year longitudinal study in a southern European population

  • Lobo, E.
  • Marcos, G.
  • Santabárbara, J.
  • Salvador-Rosés, H.
  • Lobo-Escolar, L.
  • De la Camara, C.
  • Aso, A.
  • Lobo-Escolar, A.
  • Saz, P.
  • Ventura, T.
  • Quintanilla, M.A.
  • Día, J.L.
  • Campayo, A.
  • López-Antón, R.
  • Gracia-García, P.
  • Roy, F.
  • Montañés, J.A.
  • Aznar, S.
  • Lobo, A.
Objectives To analyze independently in men and women the incidence rate of and risk factors for hip fracture in a southern European population. Illiteracy, dementia, clinically significant depression and disability were factors to receive special emphasis. Study design A community sample of 4803 individuals aged over 55 years was assessed in a two-phase case-finding study in Zaragoza, Spain, and was followed up for 16 years. Medical history and psychiatric history were collected with standardized instruments, including the History and Aetiology Schedule, the Geriatric Mental State (GMS) scale, and a Risk Factors Questionnaire. Operational criteria were used to define covariates, including diagnostic criteria for both dementia and depression. The statistical analysis included calculations of incidence rate, IR; women/men incidence rate ratio (IRR); and Hazard Ratios (HR) in multivariate Cox proportional hazards regression models. Main outcome measures Cases of hip fracture (International Classification of Diseases, WHO) identified in the treating hospitals, validated by blinded researchers. Results Hip fractures were more frequent among women than men (IRR = 3.1). Illiteracy (HR = 1.55) and depression (HR = 1.44) increased the risk in women, and smoking (HR = 2.13) and disability in basic activities of daily living (HR = 3.14) increased the risk in men. Dementia was associated with an increased risk in an univariate analysis, but the association disappeared (power = 85% in men, 95% in women) when disability was included in the multivariate models. Conclusions The IR of hip fractures was three times higher among women. Illiteracy and clinically significant depression among women and active smoking and disability (HR = 3.14) among men independently increased the risk, but dementia did not.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Gender differences in the association of cognitive impairment with the risk of hip fracture in the older population

  • Lobo, E.
  • Marcos, G.
  • Santabárbara, J.
  • Lobo-Escolar, L.
  • Salvador-Rosés, H.
  • De la Cámara, C.
  • López-Antón, R.
  • Gracia-García, P.
  • Lobo-Escolar, A.
Objectives: To test the hypothesis that differences by gender will be observed in the association of hip fracture risk with stages of cognitive impairment; and to explore the association between Petersen''s “mild cognitive impairment” (MCI) and DSM-5 “mild neurocognitive disorder” (MND). Study design: A community sample of 4803 individuals aged 55+ years was assessed in a two-phase case-finding enquiry in Zaragoza, Spain, and was followed up for 16 years. Medical and psychiatric history was collected with standardized instruments, including the Mini-Mental Status Examination (MMSE), Geriatric Mental State (GMS), History and Aetiology Schedule, and a Risk Factors Questionnaire. The statistical analysis included calculations of Hazard Ratios (HR) in multivariate Cox proportional hazards regression models. Main outcome measures: Identified cases of hip fracture, validated by blind researchers. Results: In men, hip fracture risk was increased at the “mild” (HR = 4.99 (1.39–17.91)) and at the “severe” (HR = 9.31 (1.35–64.06)) stages of cognitive impairment, indicated by MMSE performance. In contrast, in women no association could be documented at the “mild stage” (power = 89%), and the association disappeared altogether at the “severe stage” in the final multivariate statistical model (power 100%). No association observed between hip fracture and mild cognitive impairment in both men (power = 28% for P-MCI) and women (power = 44% and 19% for Petersen''s MCI and DSM-5 MND, respectively). Conclusions: Increased hip fracture risk was associated with “mild” stages of cognitive impairment in men, but not in women. To explore the potential association with the construct MCI or MND, studies with greater statistical power would be required.
Dipòsit Digital de Documents de la UAB
Publication Artículo preliminar (WorkingPaper)

Environmental regulation, choice of instruments under imperfect compliance

  • Macho Stadler, Inés|||0000-0002-2415-7972
Compliance is an important issue in environmental regulation. In this paper, we discuss some of the key elements of the problem and analyze a situation where emissions are not random and firms are risk-neutral. We study the firm's decision on emissions and compliance when the environmental regulation is based on standards and the enforcement agency audits the firm with a certain probability. We then compare total emissions when environmental regulation is based on different instruments: standards, taxes, and tradable permits. We show that when compliance is an issue, environmental taxes are superior to the other instruments. We also analyze the (static) efficiency of the solution.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Sequential coalition formation through bilateral agreements in a cournot setting

  • Macho Stadler, Inés|||0000-0002-2415-7972
  • Pérez Castrillo, David|||0000-0002-1840-7621
  • Porteiro Fresco, Nicolás
We study a sequential protocol of endogenous coalition formation based on a process of bilateral agreements among the players. We apply the game to a Cournot environment with linear demand and constant average costs. We show that the final outcome of any subgame perfect equilibrium of the game is the grand coalition, provided the initial number of firms is high enough and they are sufficiently patient.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Winners and losers from the gradual formation of trading blocs

  • Macho Stadler, Inés|||0000-0002-2415-7972
  • Xue, Licun
Although global free trade is efficient, each country's benefit from free trade depends on the path that leads to the global free trade agreement. Using a dynamic model of trading bloc formation, we show that when global free trade is reached gradually the countries that are initially excluded gain less than the rest and may be even made worse off by the final free trade agreement than they were in the initial state of no trading blocs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Negotiation advantages of professional associations in health care

  • Barros, Pedro Pita|||0000-0002-0881-4928
  • Martínez Giralt, Xavier|||0000-0002-5185-8395
In several instances, third-party payers negotiate prices of health care services with providers. We show that a third-party payer may prefer to deal with a professional association than with the sub-set constituted by the more efficient providers, and then apply the same price to all providers. The reason for this is the increase in the bargaining position of providers. The more efficient providers are also the ones with higher profits in the event of negotiation failure. This allows them to extract a higher surplus from the third-party payer.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease

  • Caballero-Camino, F. J.
  • Rivilla, I.|||0000-0003-1984-7183
  • Herraez, Elisa
  • Briz, O.
  • Santos-Laso, A.|||0000-0001-9810-4913
  • Izquierdo-Sanchez, Laura
  • Lee-Law, P. Y.
  • Rodrigues, P. M.|||0000-0001-6193-7436
  • Munoz-Garrido, P.
  • Jin, S.
  • Peixoto, E.
  • Richard, S.
  • Gradilone, S. A.
  • Perugorria, M. J.
  • Esteller, M.|||0000-0003-4490-6093
  • Bujanda, Luis|||0000-0002-4353-9968
  • Marin, J. J. G.
  • Banales, Jesus|||0000-0002-5224-2373
  • Cossío, Fernando P.|||0000-0002-4526-2122
Background and Aims: Polycystic liver diseases (PLDs) are genetic disorders characterized by progressive development of symptomatic biliary cysts. Current surgical and pharmacological approaches are ineffective, and liver transplantation represents the only curative option. Ursodeoxycholic acid (UDCA) and histone deacetylase 6 inhibitors (HDAC6is) have arisen as promising therapeutic strategies, but with partial benefits. Approach and Results: Here, we tested an approach based on the design, synthesis, and validation of a family of UDCA synthetic conjugates with selective HDAC6i capacity (UDCA-HDAC6i). Four UDCA-HDAC6i conjugates presented selective HDAC6i activity, UDCA-HDAC6i #1 being the most promising candidate. UDCA orientation within the UDCA-HDAC6i structure was determinant for HDAC6i activity and selectivity. Treatment of polycystic rats with UDCA-HDAC6i #1 reduced their hepatomegaly and cystogenesis, increased UDCA concentration, and inhibited HDAC6 activity in liver. In cystic cholangiocytes UDCA-HDAC6i #1 restored primary cilium length and exhibited potent antiproliferative activity. UDCA-HDAC6i #1 was actively transported into cells through BA and organic cation transporters. Conclusions: These UDCA-HDAC6i conjugates open a therapeutic avenue for PLDs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Efficacy and Safety of the Combination of Pravastatin and Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma (ESTAHEP Clinical Trial)

  • Riaño, Ioana|||0000-0001-8410-2706
  • Martín, Leticia
  • Varela Calvo, Maria|||0000-0003-4288-2593
  • Serrano, Trinidad
  • Núñez, Oscar
  • Mínguez Rosique, Beatriz|||0000-0002-7276-9666
  • Rodrigues, Pedro M.
  • Perugorria, Maria J.
  • Banales, Jesus|||0000-0002-5224-2373
  • Arenas, Joaquín|||0000-0002-2877-5049
Pravastatin has demonstrated anti-tumor activity in preclinical and clinical studies. This multicentric randomized double-blind placebo-controlled phase II study (NCT01418729) investigated the efficacy and safety of sorafenib + pravastatin combination on the overall survival (OS) and time to progression (TTP) of patients with advanced hepatocellular carcinoma (aHCC). A total of 31 patients were randomized. Median OS did not differ between both groups (12.4 months for the sorafenib + pravastatin group vs. 11.6 months for the control group). Of note, however, the radiological TTP was higher in patients treated with sorafenib + pravastatin than in the control group (9.9 months vs. 3.2 months; p = 0.008). Considering all the study population, the presence of portal vein thrombosis (PVT) was associated with worse OS, being lower in patients with PVT compared to patients without PVT (6.3 months vs. 14.8 months; p = 0.026). Data also showed a decrease in OS in patients with vascular invasion (VI) compared to patients who did not present it (6.3 months vs. 14.8 months; p = 0.041). The group of patients without dermatological events (DE) showed lower OS (6.9 months vs. 14.5 months; p = 0.049). In conclusion, combination of sorafenib + pravastatin was safe and well-tolerated, prolonging the TTP of patients with aHCC but not improving the OS compared to sorafenib + placebo. The absence of PVT and VI and the development of DE are positive prognostic factors of sorafenib response
e_Buah Biblioteca Digital Universidad de Alcalá
Publication Artículo científico (JournalArticle)

Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles

  • Martínez Arranz, Ibón
  • Bruzzone, Chiara
  • Noureddin, Mazen
  • Gil Redondo, Rubén
  • Mincholé, Itziar
  • Bizkarguenaga, Maider
  • Arretxe, Enara
  • Iruarrizaga Lejarreta, Marta
  • Fernández Ramos, David
  • Lopitz Otsoa, Fernando
  • Mayo, Rebeca
  • Embade, Nieves
  • Newberry, Elizabeth
  • Mittendorf, Bettina
  • Izquierdo Sánchez, Laura
  • Smid, Vaclav
  • Arnold, Jorge
  • Iruzubieta, Paula
  • Pérez Castaño, Ylenia
  • Krawczyk, Marcin
  • Marigorta, Urko M.
  • Morrison, Martine C.
  • Kleemann, Robert
  • Martín Duce, Antonio|||0000-0001-8751-9224
  • Hayardeny, Liat
  • Vitek, Libor
  • Bruha, Radan
  • Aller de la Fuente, Rocío
  • Crespo, Javier
  • Romero Gómez, Manuel
  • Banales, Jesús M.
  • Arrese, Marco
  • Cusi, Kenneth
  • Bugianesi, Elisabetta
  • Klein, Samuel
  • Lu, Shelly C.
  • Anstee, Quentin M.
  • Millet, Oscar
  • Davidson, Nicholas O.
  • Alonso, Cristina
  • Mato, José M.
14 p., Background and aims: We previously identified subsets of patients with NAFLD with different metabolic phenotypes. Here we align metabolomic signatures with cardiovascular disease (CVD) and genetic risk factors. Approach and results: We analyzed serum metabolome from 1154 individuals with biopsy-proven NAFLD, and from four mouse models of NAFLD with impaired VLDL-triglyceride (TG) secretion, and one with normal VLDL-TG secretion. We identified three metabolic subtypes: A (47%), B (27%), and C (26%). Subtype A phenocopied the metabolome of mice with impaired VLDL-TG secretion; subtype C phenocopied the metabolome of mice with normal VLDL-TG; and subtype B showed an intermediate signature. The percent of patients with NASH and fibrosis was comparable among subtypes, although subtypes B and C exhibited higher liver enzymes. Serum VLDL-TG levels and secretion rate were lower among subtype A compared with subtypes B and C. Subtype A VLDL-TG and VLDL-apolipoprotein B concentrations were independent of steatosis, whereas subtypes B and C showed an association with these parameters. Serum TG, cholesterol, VLDL, small dense LDL5,6 , and remnant lipoprotein cholesterol were lower among subtype A compared with subtypes B and C. The 10-year high risk of CVD, measured with the Framingham risk score, and the frequency of patatin-like phospholipase domain-containing protein 3 NAFLD risk allele were lower in subtype A. Conclusions: Metabolomic signatures identify three NAFLD subgroups, independent of histological disease severity. These signatures align with known CVD and genetic risk factors, with subtype A exhibiting a lower CVD risk profile. This may account for the variation in hepatic versus cardiovascular outcomes, offering clinically relevant risk stratification., National Institutes of Health (USA), Netherlands Organization for Applied Scientific Research (TNO) (Países Bajos), Newcastle NIHR Biomedical Research Center, Czech Ministry of Health, Ministerio de Economía y Competitividad, Instituto de Salud Carlos III, Fondo Europeo de Desarrollo Regional (FEDER), Departamento de Industria, Transición Energética y Sostenibilidad (Gobierno Vasco), Fundación La Caixa, Unión Europea, Fondo Nacional de Desarrollo Científico y Tecnológico (Fondecyt) (Chile), Comisión Nacional de Investigación, Ciencia y Tecnología (Chile), Agencia Nacional de Investigación y Desarrollo (ANID) (Chile)
e_Buah Biblioteca Digital Universidad de Alcalá
Publication Libro o Monografía (Book)

Españoles de Marruecos: la construcción de una identidad

  • Felipe Rodríguez, Elena de Jesús de|||0000-0002-1548-2466
  • Rodríguez Mediano, Fernando
Comunidad de Madrid
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Dual targeting of histone methyltransferase G9a and DNA-methyltransferase 1 for the treatment of experimental hepatocellular carcinoma

  • Bárcena-Varela, Marina
  • Caruso, Stefano
  • Llerena, Susana
  • Álvarez-Sola, Gloria
  • Uriarte, Iker
  • Latasa, Maria Ujue
  • Urtasun Alonso, Raquel
  • Rebouissou, Sandra
  • Álvarez Fraga, Laura
  • Jiménez, Maddalen
  • Santamaría, Eva
  • Rodriguez-Ortigosa, Carlos
  • Mazza, Giuseppe
  • Rombouts, Krista
  • San José Eneriz, Edurne
  • Rabal, Obdulia
  • Agirre, Xabier
  • Iraburu, María
  • Santos-Laso, Álvaro
  • Bañales, Jesús María
  • Zucman-Rossi, Jessica
  • Prósper, Felipe
  • Oyarzabal, Julen
  • Berasain, Carmen
  • Ávila, Matías A.
  • Fernández-Barrena, Maite G.
Epigenetic modifications such as DNA and histone methylation functionally cooperate in fostering tumor growth, including that of hepatocellular carcinoma (HCC). Pharmacological targeting of these mechanisms may open new therapeutic avenues. We aimed to determine the therapeutic efficacy and potential mechanism of action of our dual G9a histone‐methyltransferase and DNA‐methyltransferase 1 (DNMT1) inhibitor in human HCC cells and their crosstalk with fibrogenic cells. The expression of G9a and DNMT1, along with that of their molecular adaptor ubiquitin‐like with PHD and RING finger domains‐1 (UHRF1), was measured in human HCCs (n = 268), peritumoral tissues (n = 154), and HCC cell lines (n = 32). We evaluated the effect of individual and combined inhibition of G9a and DNMT1 on HCC cell growth by pharmacological and genetic approaches. The activity of our lead compound, CM‐272, was examined in HCC cells under normoxia and hypoxia, human hepatic stellate cells and LX2 cells, and xenograft tumors formed by HCC or combined HCC+LX2 cells. We found a significant and correlative overexpression of G9a, DNMT1, and UHRF1 in HCCs in association with poor prognosis. Independent G9a and DNMT1 pharmacological targeting synergistically inhibited HCC cell growth. CM‐272 potently reduced HCC and LX2 cells proliferation and quelled tumor growth, particularly in HCC+LX2 xenografts. Mechanistically, CM‐272 inhibited the metabolic adaptation of HCC cells to hypoxia and induced a differentiated phenotype in HCC and fibrogenic cells. The expression of the metabolic tumor suppressor gene fructose‐1,6‐bisphosphatase (FBP1), epigenetically repressed in HCC, was restored by CM‐272. Conclusion: Combined targeting of G9a/DNMT1 with compounds such as CM‐272 is a promising strategy for HCC treatment. Our findings also underscore the potential of differentiation therapy in HCC., Grants SAF2016-75972R, SAF2014-54191R and SAF2017-88933R from Ministerio de Economía, Spain. Grant FISPI16/01126, PI15/01132, and Miguel Servet Programme CON14/00129 to JMB, from Instituto de Salud Carlos III (ISCIII).